日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy

基于模型分析的成人梗阻性肥厚型心肌病患者马伐卡坦剂量建议

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13138
Merali, Samira; Salinger, David H; Palmisano, Maria; Sehnert, Amy J; Thanneer, Neelima; Back, Hyunmoon; Seroogy, Julie D; Gretler, Daniel D; Roy, Amit; Perera, Vidya
心血管
心肌病
发表日期：2024
文献求助 收藏

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

对肥厚型心肌病患者进行马伐卡坦药代动力学特征分析，以指导剂量滴定

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13197
Chang, Peter; Perera, Vidya; Salinger, David H; Merali, Samira; Thanneer, Neelima; Back, Hyunmoon; Seroogy, Julie D; Gretler, Daniel D; Sehnert, Amy J; Palmisano, Maria; Roy, Amit
心血管
心肌病
发表日期：2024
文献求助 收藏

Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults

氟康唑对健康成人单次服用fedratinib药代动力学的影响

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-022-04464-w
Chen, Yizhe; Ogasawara, Ken; Wood-Horrall, Rebecca; Thomas, Mark; Thomas, Michael; He, Bing; Liu, Liangang; Xue, Yongjun; Surapaneni, Sekhar; Carayannopoulos, Leonidas N; Zhou, Simon; Palmisano, Maria; Krishna, Gopal
发表日期：2022
文献求助 收藏

Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects

成年健康受试者体内奥扎尼莫德主要活性代谢物的浓度-QTc模型

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12580
Briggs, Emily; Chapel, Sunny; Zhang, Peijin; Palmisano, Maria; Tran, Jonathan Q
代谢
发表日期：2021
文献求助 收藏

Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects

在健康受试者中，多次给药后奥扎尼莫德及其主要活性代谢物的药代动力学，以及与拟交感神经药伪麻黄碱的药效学和药代动力学相互作用

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-020-01500-0
Tran, Jonathan Q; Zhang, Peijin; Walker, Susan; Ghosh, Atalanta; Syto, Mary; Wang, Xiaomin; Harris, Sarah; Palmisano, Maria
代谢
发表日期：2020
文献求助 收藏

A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

一项在健康受试者中开展的 I 期开放标签研究，旨在通过微量示踪剂方法评估 AG-221 的绝对生物利用度。

期刊:Oncology and Therapy
影响因子:3.2
doi:10.1007/s40487-019-0097-7
Wang, Xiaomin; Chen, Jian; Reyes, Josephine; Zhou, Simon; Palmisano, Maria; Li, Yan
发表日期：2020
文献求助 收藏

Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes

鲁斯帕特西普（一种红系成熟剂）在贫血合并骨髓增生异常综合征患者中的群体药代动力学和暴露-反应关系

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.12521
Chen, Nianhang; Kassir, Nastya; Laadem, Abderrahmane; Maxwell, Stephen E; Sriraman, Priya; Giuseppi, Ana Carolina; Ritland, Steve; Linde, Peter G; Budda, Balasubrahmanyam; Reynolds, Joseph G; Zhou, Simon; Palmisano, Maria
贫血
代谢
发表日期：2020
文献求助 收藏

Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment.

enasidenib 治疗期间内源性 CYP3A 诱导标志物 4β-羟基胆固醇的建模和模拟

期刊:Clinical Pharmacology-Advances and Applications
影响因子:2.5
doi:10.2147/CPAA.S192687
Li Yan, Connarn Jamie N, Chen Jian, Tong Zeen, Palmisano Maria, Zhou Simon
其它
发表日期：2019
文献求助 收藏

Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia

费德拉替尼在骨髓纤维化、真性红细胞增多症和原发性血小板增多症患者中的群体药代动力学

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-019-03929-9
Ogasawara, Ken; Zhou, Simon; Krishna, Gopal; Palmisano, Maria; Li, Yan
血小板
细胞生物学
红细胞
发表日期：2019
文献求助 收藏

An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics

一项开放标签的 1 期研究，旨在评估肝功能损害对泊马度胺药代动力学的影响

期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.470
Li, Yan; Wang, Xiaomin; Liu, Liangang; Zhang, Chengyue; Gomez, Diana; Reyes, Josephine; Palmisano, Maria; Zhou, Simon
发表日期：2019
文献求助 收藏